Cancer Communications
indexed by SCI
BMC

doi: 10.5732/cjc.011.10084
Ubc9 expression predicts chemoresistance in breast cancer
Shi-Feng Chen, Chang Gong, Ming Luo, He-Rui Yao, Yun-Jie Zeng, Feng-Xi Su
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, P. R. China.zyj81332590@126.com
[Abstract] Ubiquitin-conjugating enzyme 9 (Ubc9), the sole conjugating enzyme for sumoylation, regulates protein function and plays an important role in tumorigenesis. Whether Ubc9 is involved in the chemoresistance of breast cancer remains unknown. In this study, we aimed to evaluate the contribution of Ubc9 in the chemoresistance of breast cancer. Immunohistochemistry (IHC) was used to examine the expression level of Ubc9. Chi-square test, Wilcoxon test, and one-way ANOVA were applied to analyze the relationship between Ubc9 expression, clinicopathologic features, and clinical response to neoadjuvant chemotherapy. The significance of variables for survival was analyzed by the Cox proportional hazards model in a multivariate analysis. Kaplan-Meier survival curves were plotted and log-rank test was performed. The proportion of Ubc9-positive cells was higher in invasive ductal carcinoma than in normal breast tissues [(48.48 ± 17.94)% vs. (5.82 ± 2.80)%, P < 0.001]. High Ubc9 expression was associated with poor differentiation (&KHgr;2 = 6.538, P = 0.038), larger tumor size (&KHgr;2 = 4.701, P = 0.030), advanced clinical stage (&KHgr;2 = 4.651, P = 0.031), lymph node metastasis (&KHgr;2 = 9.913, P = 0.010), basal-like phenotype (&KHgr;2 = 8.660, P = 0.034), and poor clinical response to neoadjuvant chemotherapy (&KHgr;2 = 11.09, P = 0.001). The expected 6-year cumulative disease-free survival rate was 87.32% in patients with low Ubc9 expression compared to 68.78% in those with high Ubc9 expression (&KHgr;2= 4.289, P = 0.038). These data indicate that high Ubc9 expression correlates with poor response to chemotherapy and poor clinical prognosis.
Chinese Journal of Cancer 2011, Volume: 30, Issue 9, Page: 638-644
[ PDF Full-text ]
[Google Scholar]


Cite this article

Shi-Feng Chen, Chang Gong, Ming Luo, He-Rui Yao, Yun-Jie Zeng, Feng-Xi Su. Ubc9 expression predicts chemoresistance in breast cancer. Chin J Cancer. 2011, 30(9):638-644. doi:10.5732/cjc.011.10084


Export citations

EndNote


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by Wiley

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China